2023

1. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

   The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189